Advertisement

Management of the Late Menopause: Ultra Low-Dose Adjustive Estrogen Therapy

  • Morris Notelovitz
Part of the Medical Science Symposia Series book series (MSSS, volume 13)

Abstract

Women over 65 years of age do benefit from hormone therapy, but compliance is often poor because of estrogen-induced side effects and fear of breast cancer. Ultra low-dose estrogen therapy (ULET), adjusted to the need of the individual is effective in meeting various therapeutic goals while minimizing unacceptable side effects. The four main principles of ULET include: individualizing therapy by patient examination and selective testing; prescription of the lowest effective dose of a natural estrogen; choosing the route of administration based on the patient’s preference and medical need; adjusting the therapy over time by monitoring symptomatic and specific biologic end-point responses.

Keywords

Bone Mineral Density Estrogen Therapy Endometrial Hyperplasia Lower Effective Dose Unacceptable Side Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Notelovitz M. Estrogen therapy in the management of problems associated with urogenital aging: A simple diagnostic test and the effect of the route of hormone administration. Maturitas 1995;22(Suppl.):31–33.CrossRefGoogle Scholar
  2. 2.
    Bauer DC, Nevitt MC, Ettinger B, et al. Women with low serum estradiol have an increased risk of hip and vertebral fractures: A prospective study. In: Parapoulos SE, Lips P, Pols HAP et al., editors. Osteoporosis 1996. Proceedings of the 1996 World Congress on Osteoporosis. Amsterdam: Elsevier, 1996:271–75.Google Scholar
  3. 3.
    Genant HK, Lucas J, Weiss S, et al. Low-dose esterified estrogen therapy effects on bone, plasma estradiol concentrations, endometrium and lipid levels. Arch Int Med 1997;157:2609–15.CrossRefGoogle Scholar
  4. 4.
    Notelovitz M, Varner RE, Rebar RW, et al. Minimal endometrial proliferation over a two-year period in postmenopausal women taking 0.3 mg of unopposed esterified estrogen. Menopause 1997;2:80–88.Google Scholar
  5. 5.
    Stadberg E, Mattson LA, Uvebrant M. 17β estradiol and norethindrone acetate in low doses as continuous combined hormone replacement therapy. Maturitas 1996;23:31–39.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers and Fondazione Giovanni Lorenzini 1999

Authors and Affiliations

  • Morris Notelovitz

There are no affiliations available

Personalised recommendations